Table II.
Characteristics of the debridement, antibiotics, and implant retention protocols included in the series.
| Variable | Data | p-value |
|---|---|---|
| Surgeon’s experience, n (%) | ||
| Consultant | 53 (55.2) | 0.622 |
| Fellow | 43 (44.8) | |
| Exchange of modular components | 1 (1.0) | N/A |
| Irrigating solution, n (%) | ||
| Saline | 24 (25) | 0.462 |
| Betadine | 56 (58.4) | |
| Chlorhexidine | 8 (8.3) | |
| Others (rifocin) | 8 (8.3) | |
| Use of local antibiotic power, n (%) | 14 (14.6) | 0.321 |
| Causative organism, n (%) | ||
| MSSA | 20 (20.8) | 0.061 |
| MRSA | 9 (9.4) | |
| S. epidermidis | 12 (12.5) | |
| Escherichia coli | 6 (6.3) | |
| Pseudomonas aeruginosa | 7 (7.3) | |
| Others (Streptococcus agalactiae, Streptococcus viridans, Cutibacterium acnes, Proteus mirabilis, Corynebacterium spp, Enterobacter, etc) | 13 (13.5) | |
| Polymicrobial | 10 (10.4) | |
| Negative culture | 19 (19.8) | |
| Mean duration of postoperative antibiotherapy, mnths (SD) | 39.33 (28.4) | 0.581 |
| Chronic suppressive antibiotherapy, n (%) | 6 (6.25) | 0.342 |
*
Association with DAIR failure.
DAIR, debridement, antibiotics, and implant retention; MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-sensitive Staphylococcus aureus; N/A, not applicable; spp, species.